In BARDOT, those treated conservatively had considerably lower rates of antiplatelet agents and statins prescribed; hence, there appears to be an opportunity to optimize medical therapy in those with normal nuclear stress tests. What the BARDOT trial has taught us is that in the modern era of multidrug DM treatment and risk factor control in asymptomatic patients, screening for significant CAD has a high yield and those found to have disease have event rates (approximately 10%) similar to those with symptomatic CAD who would have come to attention for revascularization.
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